Leqembi: Side Effects, Uses, Cost, Similar Drugs, Dosage, and More

Alzheimer’s disease can feel like a long, confusing maze. Leqembi
(lecanemab-irmb) is one of the newest tools doctors have added to the map.
It’s not a cure, and it’s not a miracle “memory pill,” but it does offer
a way to slow down early Alzheimer’s in some people. If you’ve heard about
Leqembi in the news, from a friend, or in your doctor’s office and thought,
“Okay, but what does this actually mean for real life?” this guide is for you.

Below, we’ll walk through what Leqembi is, how it works, who might be a
candidate, common side effects and serious risks, how much it costs, how it’s
given (including the newer injectable option), how it compares with similar
drugs, and what questions to ask your healthcare team. We’ll also share
practical, real-life experiences of what treatment can feel like for
patients and caregivers.

What Is Leqembi?

Leqembi is a prescription medication used to treat adults with
early Alzheimer’s disease specifically people with
mild cognitive impairment (MCI) or mild dementia due to
Alzheimer’s and confirmed amyloid plaques in the brain. It belongs to a
class of drugs called amyloid beta–directed antibodies. In
plain English: it’s a lab-made antibody that targets the sticky protein
clumps (amyloid plaques) that build up in the brains of people with
Alzheimer’s.

The U.S. Food and Drug Administration (FDA) first granted Leqembi
accelerated approval in 2023, and later converted this to full (traditional)
approval after a large phase 3 trial showed that the drug slowed
cognitive and functional decline in people with early Alzheimer’s compared
with placebo. It’s the first anti-amyloid Alzheimer’s drug in the U.S. to
achieve traditional approval based on demonstrated clinical benefit.

How Leqembi Works in the Brain

Leqembi is a monoclonal antibody that recognizes and binds to aggregated
forms of amyloid beta. Once it locks onto these clumps, the immune system
helps clear them away. Over time, this reduces amyloid plaque levels as
seen on brain imaging. In clinical trials, people on Leqembi showed:

• A significant reduction in amyloid plaque on PET scans.
• A slower rate of decline in memory, thinking, and daily functioning compared with placebo over 18 months.
• Benefits that were modest but meaningful for some patients and families.

Important reality check: Leqembi does not restore lost
memory, and it doesn’t stop the disease forever. Think of it more as tapping
the brakes rather than slamming them to a full stop.

Who Can Use Leqembi?

Leqembi is not for everyone with memory problems. Doctors typically consider
it for people who meet all of the following:

• Diagnosis of early Alzheimer’s disease with mild cognitive
  impairment or mild dementia.
• Confirmed amyloid pathology (usually via a PET scan or
  cerebrospinal fluid/blood tests).
• No major medical reasons to avoid therapy, such as certain bleeding risks
  or recent serious brain bleeds.
• Ability to attend frequent infusions or manage regular injections, plus
  regular brain MRI monitoring.

Before starting Leqembi, your healthcare team will review your medical
history, medications (especially blood thinners), and brain imaging. Many
centers also recommend or offer testing for the ApoE ε4
gene, which can influence the risk of certain side effects.

ApoE ε4 and Risk Considerations

People who carry the ApoE ε4 genetic variant, especially
those with two copies (homozygotes), have a higher risk of a serious side
effect called ARIA (more on this below). Having ApoE ε4 doesn’t
automatically mean you can’t use Leqembi, but it does mean the risk–benefit
calculation needs careful discussion. Some regulators and guidelines are
more cautious in ApoE ε4 homozygotes.

How Is Leqembi Given? Dosage and Administration

Leqembi started as an intravenous (IV) infusion only, but newer options now
exist. Dosing and the way it’s given have evolved, so it’s helpful to break
it down into phases.

1. Intravenous (IV) Treatment Phase

The classic way Leqembi is used is through an IV infusion, where the drug
is delivered directly into a vein at an infusion center, hospital, or
clinic.

• Typical dosing: 10 mg per kilogram of body weight, given
  every two weeks for the first 18 months of treatment (per traditional
  label schedules).
• Infusion time: Usually about an hour, plus extra time for
  check-in, pre-medications (if needed), and observation afterwards.
• Monitoring: Brain MRIs are done at specific times early
  in treatment and when symptoms suggest side effects like ARIA.

After the initial intensive phase, some patients transition to less
frequent maintenance dosing or to a subcutaneous (under-the-skin)
formulation.

2. Maintenance IV and the New Injectable (Subcutaneous) Option

Recent approvals have added a maintenance dosing phase:

• Maintenance IV: After 18 months of every-2-week IV
  treatment, many patients can switch to IV maintenance infusions once
  every four weeks (10 mg/kg).
• Subcutaneous (SC) Leqembi IQLIK: An FDA-approved
  at-home injectable option for maintenance dosing after the initial IV
  course. It’s given as a 360 mg subcutaneous injection once a week using a prefilled autoinjector.

The injectable version aims to make treatment more convenient fewer clinic
visits, more flexibility, and a familiar “pen-like” device similar to those
used in diabetes or weight-loss medications. However, regular MRI
monitoring and follow-up visits are still necessary.

Leqembi Side Effects: From Mild to Serious

Every medication has side effects, and Leqembi is no exception. Because it
acts on the brain, some of its side effects are unique and potentially
serious. It’s important to know what’s common, what’s rare but serious, and
when to call your doctor or emergency services.

Common Side Effects

In clinical trials and real-world use, some of the more common side effects
include:

• Infusion-related reactions (chills, fever, nausea, blood pressure changes)
• Headache
• Fatigue
• Nausea or vomiting
• Cough or respiratory symptoms in some people
• Falls, especially in older adults

Infusion reactions most often occur during or within a few hours of the
infusion, especially the first few doses. Your care team may slow the
infusion, pause it, or give medications (like antihistamines or
acetaminophen) to manage symptoms.

The Big One: ARIA (Amyloid-Related Imaging Abnormalities)

The most talked-about risk with Leqembi is
ARIA amyloid-related imaging abnormalities. These are
changes seen on brain MRI scans that can involve:

• ARIA-E (edema): Swelling in the brain (sometimes called
  vasogenic edema or sulcal effusions).
• ARIA-H (hemosiderin): Small brain bleeds or microhemorrhages,
  or superficial siderosis (blood breakdown products on the surface of the brain).

Many people with ARIA have no symptoms and only find out
because of routine MRI monitoring. However, when symptoms do occur, they
may include:

• Worsening headache
• Confusion or new disorientation
• Dizziness or difficulty walking
• Vision changes
• Seizures
• Weakness or difficulty speaking (which can mimic a stroke)

Most ARIA cases are mild to moderate and improve when the medication is
paused or stopped. However, serious and rarely fatal brain bleeds
have been reported, especially in people with additional risk factors like
blood thinners or a history of brain hemorrhage. Because of this, the FDA
and experts recommend careful MRI monitoring and thoughtful use in people
with higher bleeding risk.

Other Serious Warnings and Precautions

Leqembi also carries other important warnings:

• Hypersensitivity reactions: Including allergic reactions,
  swelling (angioedema), bronchospasm, or even anaphylaxis. Infusions are
  done in medical settings so staff can respond quickly.
• Worsening of pre-existing small brain bleeds: People with
  many microbleeds or certain vascular conditions may be at higher risk.
• Interactions with clot-busting drugs: In people on
  anti-amyloid antibodies, using powerful thrombolytics (like tPA) for stroke
  may be more risky, so neurologists tread carefully.

As always, your healthcare provider will review your individual risks and
benefits in detail. If at any point you notice new neurologic symptoms
(sudden weakness, severe headache, confusion, seizures), seek urgent
medical care.

Leqembi Cost and Insurance Coverage

Now for the part that makes everyone’s eyebrows go up: the cost.
Leqembi is an advanced biologic medication and is priced accordingly.

List Price vs. Real-World Costs

The manufacturer’s annual list price for the IV form of
Leqembi has been around the mid–five-figure range per year (commonly cited
around $26,500 annually for the drug alone), not including:

• Infusion center fees
• Specialist visits
• Diagnostic tests like MRIs and PET scans

The newer subcutaneous autoinjector formulation has its own
list price (for example, around the high–four- to low–five-figure range per
year), reflecting the convenience of at-home dosing. Actual numbers can
change over time and vary by insurer and region.

Medicare and Other Insurance

In the U.S., coverage is evolving but generally includes:

• Medicare Part B: Leqembi is typically covered under Part B
  (as an infused or physician-administered drug). Part B usually pays about
  80% of the allowed cost after the deductible, leaving patients
  responsible for roughly 20% unless they have supplemental coverage.
• Medigap or supplemental insurance: May cover much of the
  20% coinsurance for eligible patients.
• Medicare Advantage and commercial insurance: Coverage
  policies vary and may require prior authorization, registry enrollment,
  or treatment at specialized centers.

Many patients end up paying anywhere from near $0 (with strong supplemental
coverage) to several thousand dollars a year out of pocket. Financial
counseling, specialty pharmacy services, and manufacturer assistance
programs can help families understand and potentially reduce costs.

Similar Drugs and How They Compare

Leqembi is part of a new wave of disease-modifying Alzheimer’s drugs.
Here’s how it sits in the current landscape.

Kisunla (donanemab)

Kisunla (donanemab) is another anti-amyloid monoclonal antibody used for
early Alzheimer’s disease. Like Leqembi, it:

• Targets amyloid plaques in the brain.
• Requires regular infusions and MRI monitoring.
• Has ARIA as a key side effect risk.

Differences may include dosing schedules, how long treatment continues,
population eligibility, and specific trial results. Both medications are
high-cost and generally covered under Medicare Part B with similar
financial implications.

Aduhelm (aducanumab)

Aduhelm was an earlier anti-amyloid drug that received accelerated approval
but faced substantial controversy over its benefit–risk profile and cost.
Medicare later restricted coverage, and the manufacturer eventually
discontinued the product. Its story helped shape the stricter scrutiny and
evidence requirements applied to Leqembi and newer drugs.

Traditional Symptom-Targeting Drugs

Even with Leqembi, most people with Alzheimer’s will still be offered
traditional medications that target symptoms, such as:

• Cholinesterase inhibitors: Donepezil, rivastigmine, galantamine.
• NMDA receptor antagonist: Memantine.

These treatments don’t remove amyloid, but they can help support memory,
attention, or daily functioning for some people, especially in the short to
medium term. In practice, many patients on Leqembi also take one or more of
these medications.

Drug Interactions and Precautions

Leqembi is not a pill you grab off a pharmacy shelf; it’s a complex biologic
given under careful supervision. Some key precautions include:

• Blood thinners (anticoagulants, antiplatelets): Because
  Leqembi can increase the risk of brain bleeding in some people, combining
  it with strong blood thinners may raise risk further. This doesn’t
  automatically rule it out, but it requires a careful risk–benefit
  discussion.
• Past brain hemorrhage or many microbleeds on MRI: These
  findings may increase the risk of serious ARIA-H.
• Other neurologic conditions: Stroke, seizures, or
  vascular malformations may complicate decision-making.

Always give your neurology team a full list of medications, supplements,
and medical conditions before starting treatment. That includes over-the-counter drugs and “just vitamins”they all matter.

Frequently Asked Questions About Leqembi

Will Leqembi Cure Alzheimer’s?

No. Leqembi doesn’t cure Alzheimer’s and doesn’t bring memory back to
“normal.” The goal is to slow the progression of early
Alzheimer’s, hopefully preserving independence and quality of life for a
longer period.

How Soon Might Benefits Show Up?

In clinical trials, differences between Leqembi and placebo became clearer
over many months. This isn’t like pain medicine where you feel a change in
hours or days. Think of it as altering the long-term slope of decline
rather than producing an immediate “boost.”

How Long Do People Stay on Leqembi?

Long-term treatment strategies are still being refined. Many patients
follow the studied regimen (about 18 months of regular infusions) and then
continue on a maintenance schedule, either with less frequent IV infusions
or weekly injections, as long as the benefits and risks remain acceptable.

Is Leqembi Right for Every Person with Memory Loss?

Definitely not. Leqembi is specifically for people with early Alzheimer’s,
not for general age-related forgetfulness, other types of dementia (like
frontotemporal dementia or Lewy body dementia), or advanced Alzheimer’s.
Proper diagnosis and amyloid confirmation are critical.

Key Takeaways: Is Leqembi Worth Discussing with Your Doctor?

Leqembi represents a significant step forward: it’s a therapy that targets
the underlying amyloid pathology of Alzheimer’s and has been shown to slow
cognitive and functional decline in early disease. But it comes with:

• Non-trivial safety risks, especially ARIA and brain bleeds.
• Substantial costs and logistical demands (infusions, MRIs, follow-ups).
• Benefits that are modest in size, though meaningful for some patients and families.

If you or a loved one has early Alzheimer’s, it’s absolutely reasonable to
ask your neurologist:

• “Am I (or my family member) a candidate for Leqembi?”
• “What are my personal risks based on my MRI, genetics, and other health issues?”
• “How much could this realistically help, and how will we measure that?”
• “What will this cost us after insurance?”
• “How does Leqembi fit alongside other treatments and lifestyle changes?”

No article can replace a personalized conversation with your healthcare
team. But going into that conversation informed and with a list of smart
questions puts you in the driver’s seat.

Real-World Experiences and Practical Tips with Leqembi (Approx. )

What does Leqembi look like in everyday life? Let’s zoom in on the lived
experience, because treatment is about more than molecules and MRI scans.

Picture a typical patient: someone in their late 60s or early 70s who’s
started misplacing bills, repeating stories, or getting turned around in
familiar neighborhoods. After months of evaluations memory testing, blood
work, maybe a spinal tap or PET scan the diagnosis lands: early
Alzheimer’s disease. It’s a punch to the gut, even if everyone suspected
it. When Leqembi enters the conversation, it often comes with mixed
emotions: hope, anxiety, and a lot of “what ifs.”

The first infusion day can feel like starting a new chapter. Some families
treat it almost like a mini milestone: they bring snacks, a tablet,
headphones, maybe a favorite blanket. There might be pre-infusion
medications, vital-sign checks, and then the slow drip of the medication.
Many patients feel fine; some get chills, a mild headache, or feel a bit
“off” later that day. Most centers watch patients closely during the first
few infusions to catch any serious infusion reaction early.

Over time, the rhythm of infusions every two weeks becomes part of the
household schedule, like a recurring appointment on a shared calendar.
Caregivers often build routines around it: grocery runs while their loved
one is in the chair, catching up on work emails, or chatting with other
families in the waiting room. Some find comfort in seeing the same nurses
and staff each visit; the infusion center becomes an unexpected extension
of the support network.

The tough moments often happen around MRI scans or new symptoms. Maybe a
patient reports worsening headaches or a spell of confusion. The care team
orders an extra MRI to check for ARIA, and anxiety spikes while everyone
waits for results. If ARIA is found, treatment may be paused. Those
conversations “We need to step back for safety” can be emotionally
heavy, especially for families who pinned big hopes on the therapy. On the
flip side, when ARIA resolves and treatment resumes safely, there’s often a
sense of cautious relief.

Financial stress is another real-world layer. Even with Medicare Part B and
supplemental coverage, coinsurance, deductibles, and associated costs (like
imaging and specialist visits) can add up. Many families end up talking
with hospital financial counselors, social workers, or patient assistance
programs. It’s not glamorous, but those phone calls and forms are often
what make ongoing treatment feasible.

Emotionally, caregivers frequently measure “success” in small victories:
another holiday where their loved one remembers everyone’s names, another
year where they can still manage their own grooming, make simple meals, or
enjoy a favorite hobby. The decline may still be there, but a little
slower like someone gradually turning down the dimmer switch instead of
flipping the lights off all at once.

The newer at-home injectable option changes the texture of daily life for
some families. Instead of biweekly drives to an infusion center, there’s a
weekly routine at home cleaning a small area, prepping the pen,
double-checking instructions, and giving the injection. It can feel more
empowering for some, and more nerve-wracking for others. Training from the
healthcare team is essential, and most patients and caregivers become
surprisingly adept with time.

Ultimately, people who feel most satisfied with Leqembi regardless of the
exact degree of benefit are those who view it as one piece of a larger
care plan. They combine it with regular exercise, heart-healthy eating,
social engagement, cognitive activities, treatment of other health
conditions, and practical planning for the future. The medication can help
slow the disease, but the day-to-day choices, support systems, and
relationships are what fill those extra months or years with meaning.

If you’re considering Leqembi, think about it like joining a long-term
team sport: you, your loved ones, your doctors, and the medication all play
a role. Ask questions, plan for the practical details, and give yourself
permission to feel hopeful and cautious at the same time both are valid.

Conclusion

Leqembi is a major milestone in Alzheimer’s treatment: it slows early
disease by targeting a key driver of pathology. But it comes wrapped in
complexity serious potential side effects, high costs, and demanding
logistics. For some individuals, the trade-off is absolutely worth it; for
others, the risks, burdens, or financial strain may outweigh the benefit.

The best next step is a frank, detailed conversation with your neurologist
or memory specialist. Bring questions, bring a trusted family member or
friend, and bring an open mind. Whether you choose Leqembi, another therapy,
or supportive care only, you deserve a plan that respects both the science
and the realities of your life.

Disclaimer: This article is for educational purposes only and is not a
substitute for professional medical advice. Always consult your healthcare
provider about diagnosis, treatment options, risks, and benefits that apply
to your specific situation.